Johnson & Johnson is moving out from the diabetes business and sold its Calibra product (marketed as OneTouch Via, but never launched) to a 10-year-old company named CeQur, which was already working on a similar insulin-delivery wearable. The terms and conditions of this deal have not yet been yet disclosed, but CeQur has attained an exclusive worldwide license for this technology.
Boehringer Ingelheim has reason to believe its diabetes medication Jardiance can help fend off cardiovascular death, kidney failure and hospitalization for heart failure. And now, it’s developing a model to help predict which patients are best suited for treatment with the therapy.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.